Tysabri Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Differential Runx3, Eomes, and T-bet expression subdivides MS-associated CD4 < sup > + < /sup > T cells with brain-homing capacity
This article is protected by copyright. All rights reserved.PMID:38009648 | DOI:10.1002/eji.202350544 (Source: European Journal of Immunology)
Source: European Journal of Immunology - November 27, 2023 Category: Allergy & Immunology Authors: Cindy Hoeks Fabi ënne van Puijfelik Steven C Koetzier Jasper Rip Cato E A Corsten Annet F Wierenga-Wolf Marie-Jos é Melief Piet Stinissen Joost Smolders Niels Hellings Bieke Broux Marvin M van Luijn Source Type: research

Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis —Variations in Real-World Experience—Reply
In Reply We thank Dr Wolf and colleagues for highlighting the importance of clinical context when evaluating effectiveness of multiple sclerosis (MS) therapies. As demonstrated in the comparative effectiveness of natalizumab and fingolimod, where seemingly discordant results emerged from different registries, characteristics of the study population play a central role in study findings. It is, therefore, important to differentiate between studies of treatment efficacy and effectiveness. (Source: JAMA Neurology)
Source: JAMA Neurology - November 20, 2023 Category: Neurology Source Type: research

Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
Conclusions The effectiveness of natalizumab and fingolimod in active RRMS is superior to dimethyl fumarate, teriflunomide, glatiramer acetate and interferon beta. This study demonstrates the utility of MSM in emulating trials to compare clinical effectiveness among multiple interventions simultaneously. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 15, 2023 Category: Neurosurgery Authors: Diouf, I., Malpas, C. B., Sharmin, S., Roos, I., Horakova, D., Kubala Havrdova, E., Patti, F., Shaygannejad, V., Ozakbas, S., Eichau, S., Onofrj, M., Lugaresi, A., Alroughani, R., Prat, A., Duquette, P., Terzi, M., Boz, C., Grand'Maison, F., Sola, P., Fer Tags: Editor's choice Multiple sclerosis Source Type: research

Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study
Patient-reported outcomes (PRO) are increasingly utilized as part of the routine clinical assessment in people with multiple sclerosis (pwMS). The long-term effect of disease modifying therapies (DMTs) and their discontinuation on PRO measures remains largely unknown. (Source: Journal of the Neurological Sciences)
Source: Journal of the Neurological Sciences - November 13, 2023 Category: Neurology Authors: Dejan Jakimovski, Katelyn S. Kavak, Karen Zakalik, Corey McGraw, Malcolm Gottesman, Patricia K. Coyle, Robert Zivadinov, Bianca Weinstock-Guttman, on behalf of New York State Multiple Sclerosis Consortium (NYSMSC) Source Type: research

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
Discussion Patients with MS have higher risks of outpatient and serious infections compared with patients without MS. The risk of outpatient infections was similarly increased by rituximab and fingolimod and serious infections by rituximab and natalizumab compared with IFN/GLAT. Steps to minimize risks include optimizing bladder care, comorbidity prevention, varicella vaccination, and considering discontinuing or avoiding DMT use in patients with advanced disability and/or previous hospitalizations for infections. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - October 9, 2023 Category: Neurology Authors: Langer-Gould, A. M., Smith, J. B., Gonzales, E. G., Piehl, F., Li, B. H. Tags: Multiple sclerosis Research Article Source Type: research

The Prevalence of Cancer in Patients with Multiple Sclerosis (MS) who were Under Treatment with Natalizumab (Tysabri): A Systematic Review and Meta ‑Analysis
Conclusions: The main finding of this systematic review and metaanalysis is that the pooled prevalence of cancer in subjects who suffer from MS and received natalizumab was 2%. (Source: International Journal of Preventive Medicine)
Source: International Journal of Preventive Medicine - October 4, 2023 Category: International Medicine & Public Health Source Type: research

Comparing persistence of new biologics to conventional anti-TNF alphas in adult patients with inflammatory bowel disease: a systematic review and meta-analysis protocol
Background Biological therapy is a cornerstone of managing moderate-to-severe inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn’s disease (CD). New biologics have been evolving over the past 20 years and selection of an agent remains challenging. Drug persistence measures the duration of time from initiation to discontinuation of a therapy, which can be a surrogate marker of drug tolerance and efficacy. Objectives The study aimed to compare drug persistence of new generation biologics for the treatment of UC and CD (vedolizumab, ustekinumab, certolizumab, tofacitinib, natalizumab and golimumab) wit...
Source: BMJ Open - October 3, 2023 Category: General Medicine Authors: Yiu, T. H., Ko, Y., Pudipeddi, A., Natale, P., Leong, R. W. Tags: Open access, Gastroenterology and hepatology Source Type: research

Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin {beta}7+ Compartment
Discussion Our study shows that circulating integrin β7+ memory CD4 T cells of patients with relapsing-remitting MS under natalizumab are enriched in proinflammatory cells supporting the hypothesis that integrin β7+ memory CD4 T cells could play a pathogenic role in the disease rebound observed at natalizumab discontinuation. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - September 22, 2023 Category: Neurology Authors: Nguyen Ky, M., Duran, A., Hasantari, I., Bru, A., Deloire, M., Brochet, B., Ruet, A., Schmitt, N. Tags: All Immunology, Multiple sclerosis Research Article Source Type: research

Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies
ConclusionsVaccination effectively protects pwMS from COVID-19. An increased risk of breakthrough infection was noted on high-efficacy DMTs, however COVID-19 after vaccination was usually mild. (Source: Journal of Neurology)
Source: Journal of Neurology - September 20, 2023 Category: Neurology Source Type: research

Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
AbstractAfter more than 2 decades of recommending an escalating strategy for the treatment of most patients with multiple sclerosis, there has recently been considerable interest in the use of high-efficacy therapies in the early stage of the disease. Early intervention with induction/high-efficacy disease-modifying therap y may have the best risk-benefit profile for patients with relapsing-remitting multiple sclerosis who are young and have active disease, numerous focal T2 lesions on spinal and brain magnetic resonance imaging, and no irreversible disability. Although we have no curative treatment, at least seven cl as...
Source: Drugs - September 19, 2023 Category: Drugs & Pharmacology Source Type: research

Intravenous or subcutaneous natalizumab in patients with relapsing –remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study
ConclusionsSC natalizumab administration will consistently reduce consumption of patient and HCP times per procedure and associated costs. (Source: Journal of Neurology)
Source: Journal of Neurology - September 16, 2023 Category: Neurology Source Type: research

Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis
Conclusions Older age is associated with a lower prevalence and degree of focal inflammatory disease activity in treated and untreated RRMS. Our findings inform the design of RCTs, and suggest that patient age should be taken into consideration when deciding on immunomodulatory treatment in RRMS. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - September 14, 2023 Category: Neurosurgery Authors: Strijbis, E. M., Coerver, E., Mostert, J., van Kempen, Z. L. E., Killestein, J., Comtois, J., Repovic, P., Bowen, J. D., Cutter, G., Koch, M. Tags: Multiple sclerosis Source Type: research